Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks

Annals of Allergy, Asthma and Immunology

Volumn 105, Issue 2, 2010, Pages 149-154

  Bernstein, Jonathan A ^a   Ritchie, Bruce ^b   Levy, Robyn J ^c   Wasserman, Richard L ^d   Bewtra, Againdra K ^e   Hurewitz, David S ^f   Obtulowicz, Krystyna ^g   Reshef, Avner ^h   Moldovan, Dumitru ⁱ   Shirov, Todor ^j   Grivcheva Panovska, Vesna ^k   Kiessling, Peter C ^l   Schindel, Fritz ^m   Craig, Timothy J ⁿ  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Family Allergy and Asthma Center   (United States)

^d DallasAllergyImmunology   (United States)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Allergy Clinic of Tulsa Inc   (United States)

^g JAGIELLONIAN UNIVERSITY   (Poland)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^j UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^k PHI University Clinical Center   (Macedonia)

^l CSL BEHRING GMBH   (Germany)

^m ACCOVION GMBH   (Germany)

ⁿ PENN STATE COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; PLACEBO;

ABDOMINAL DISEASE; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FACE EDEMA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHARMACOLOGICAL PARAMETERS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BIOLOGICAL MODEL; BLOOD; GENETICS; HALF LIFE TIME; HEREDITARY ANGIOEDEMA TYPES I AND II; MIDDLE AGED; POPULATION GROUP; VERY ELDERLY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COMPLEMENT C1 INHIBITOR PROTEIN; HALF-LIFE; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; POPULATION GROUPS; RETROSPECTIVE STUDIES;

EID: 77955191013     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2010.06.005     Document Type: Article

References (28)

1. K. Bork Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions Expert Rev Clin Immunol 4 2008 13 20
2. T. Bowen, M. Cicardi, and K. Bork Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema Ann Allergy Asthma Immunol 100 suppl 2 2008 S30 S40
3. A.E. Davis The pathophysiology of hereditary angioedema Clin Immunol 114 2005 3 9
4. A. Agostoni, E. Aygren-Prsn, and K.E. Binkley Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond J Allergy Clin Immunol 114 suppl 2004 S51 S131
5. K. Bork, S.E. Barnstedt, P. Koch, and H. Traupe Hereditary angioedema with normal C1-inhibitor activity in women Lancet 356 2000 213 217
6. T. Bowen, M. Cicardi, and H. Farkas Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema J Allergy Clin Immunol 114 2004 629 637
7. M. Cugno, A. Zanichelli, F. Foieni, S. Caccia, and M. Cicardi C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress Trends Mol Med 15 2009 69 78
8. G. Dewald, and K. Bork Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor Biochem Biophys Res Commun 343 2006 1286 1289
9. K. Bork, P. Staubach, A.J. Eckardt, and J. Hardt Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency Am J Gastroenterol 101 2006 619 627
10. J.H. Levy, and P.S. O'Donnell The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema Expert Opin Investig Drugs 15 2006 1077 1090
11. T.G. Epstein, and J.A. Bernstein Current and emerging management options for hereditary angioedema in the US Drugs 68 2008 2561 2573
12. M.M. Gompels, R.J. Lock, and M. Abinun C1 inhibitor deficiency: consensus document Clin Exp Immunol 139 2005 379 394
13. T.J. Craig, R.J. Levy, and R.L. Wasserman Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks J Allergy Clin Immunol 124 2009 801 808
14. T. Craig, M. Riedl, and M.S. Dykewicz When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 102 2009 366 372 b
15. B.L. Zuraw Novel therapies for hereditary angioedema Immunol Allergy Clin North Am 26 2006 691 708
16. 2 receptor antagonist J Allergy Clin Immunol 119 2007 S274
17. M.B. van Doorn, J. Burggraaf, T. van Dam, A. Eerenberg, M. Levi, and C.E. Hack A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema J Allergy Clin Immunol 116 2005 876 883
18. I. Martinez-Saguer, E. Rusicke, E. Aygren-Prsn, N. von Hentig, T. Klingebiel, and W. Kreuz Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study Transfusion 50 2010 354 360
19. M. Kunschak, W. Engl, and F. Maritsch A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema Transfusion 38 1998 540 549
20. C. de Zwaan, A.H. Kleine, J.H. Diris, J.F. Glatz, H.J. Wellens, and P.F. Strengers Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction Eur Heart J 23 2002 1670 1677
21. J.H. Diris, W.T. Hermens, P.W. Hemker, W.K. Lagrand, C.E. Hack, and M.P. van Dieijen-Visser Pharmacokinetics of C1-inhibitor protein in patients with acute myocardial infarction Clin Pharmacol Ther 72 2002 498 504
22. B. Blask, G. Szplaki, and L. Varga Relationship between copy number of genes (C4A, C4B) encoding the fourth component of complement and the clinical course of hereditary angioedema (HAE) Mol Immunol 44 2007 2667 2674
23. L. Varga, G. Szplaki, and B. Visy C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema: strong correlation with the severity of disease in C1-INH concentrate nave patients Mol Immunol 44 2007 1454 1460
24. Cinryze [US package insert] 2008 ViroPharma Exton, PA
25. D. Brackertz, E. Isler, and F. Kueppers Half-life of C1INH in hereditary angioneurotic oedema (HAE) Clin Allergy 5 1975 89 94
26. Lev Pharmaceuticals Inc Pharmacokinetics of C1 esterase inhibitor in hereditary angioedema subjects http://clinicaltrials.gov/ct2/show/NCT00432510? term=angioedema&rank=14 Accessed November 10, 2009
27. C. Caliezi, W.A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C.E. Hack C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema Pharmacol Rev 52 2000 91 112
28. Cinryze FDA clinical pharmacology review http://www.fda.gov/downloads/ BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/ FractionatedPlasmaProducts/ucm094084.pdf Accessed November 10, 2009